Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC neoSCORE

STATUS

Recruiting
participants needed

60
sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Send

Updated on 19 February 2024

See if I qualify

cancer

diabetes

pulmonary disease

platelet count

stroke

carboplatin

neutrophil count

lung cancer

pemetrexed

paclitaxel

pneumonia

granulocyte colony stimulating factor

proteinuria

myocardial infarction

hepatitis

tuberculosis

unstable angina

angina pectoris

g-csf

colony stimulating factor

liver disease

adjuvant therapy

blood test

transient ischemic attack

mental illness

sintilimab

interstitial lung disease

blood pregnancy test

non-small cell lung cancer

small cell lung cancer

Summary

Description

This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. In this trial, eligible subjects will be randomly assigned to arm A and arm B (1:1). Subjects in arm A will receive 2 cycles of neoadjuvant chemotherapy with sintilimab + chemotherapy and arm B will receive 3 cycles of neoadjuvant chemotherapy with sintilimab + chemotherapy, followed by surgery within the 4th week after the last dose of sintilimab. After operation, subjects in arm A will receive 2 cycles of adjuvant chemotherapy and arm B will receive 1 cycle of adjuvant chemotherapy, followed by the maintenance treatment of sintilimab for up to 1 year according to the requirements of patients. The primary purpose is MPR rate of neoadjuvant chemotherapy of resectable NSCLC with different cycles of sintilimab combined with platinum-based chemotherapy, which is defined as the percentage of participants having 10% viable tumor cells in the pathological examination of resected specimens.

Details

Condition	Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Age	18-75 years
Treatment	Carboplatin, Pemetrexed, Sintilimab, Albumin-Bound Paclitaxel
Clinical Study Identifier	NCT04459611
Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	b'Sign the informed consent form before starting any trial related procedure.'
	b'18-75 years old, male or female.'
	b'Non-small cell lung cancer confirmed by cytology or histology.'
	b'There must be at least one evaluable focus judged according to recist1.1 standard.'
	b'Evaluation by the researchers to confirm resectable stage c\\u2161a-\\u2162a NSCLC patients'
	b'without any treatment before.'
	b'ECOG PS 0-1.'
	b'Life expectancy > 6 months.'
	b'Adequate organ function and it should meet the following criteria:'
	b'No use of Granulocyte colony stimulating factor within 14 days, absolute'
	b'neutrophils count(ANC)\\u22651.5x109/L, platelets count(PLT)>9g/dL,'
	b'hemoglobin(HB)\\u2265100\\xd7109/L;'
	b'Total bilirubin(TBIL)\\u22641.5ULN, ALT\\u3001AST\\u2264 2.5 ULN, serum creatinine(sCr)\\u22641.5ULN;'
	b'good blood coagulation: INR\\u22641.5 or PT\\u22641.5 ULN;'
	b'normal thyroid function: TSH within normal institutional limits;'
	b'Women of childbearing age must undergo a serological pregnancy test within 3 days'
	b'before the first dose(cycle 1 day 1) with negative results. If the result of urine'
	b'pregnancy test cannot be confirmed as negative, blood pregnancy test is required.'
Exclusion Criteria
	b'Malignancies within 5 years prior to the first dose(excluding radical skin basal cell'
	b'carcinoma, skin squamous cell carcinoma and / or radical resection of carcinoma in'
	b'itu).'
	b'Currently participating in the intervention clinical treatment, or receiving other'
	b'drugs or research instruments within 4 weeks before the first dose.'
	b'Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or'
	b'drugs for another stimulation or synergistic inhibition of T cell receptor (e.g.'
	b'CTLA-4, OX-40, CD137).'
	b'Active autoimmune diseases requiring systemic treatment (e.g. using disease improving'
	b'drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first'
	b'dose. Alternative therapies (e.g. thyroxine, insulin or corticosteroids in'
	b'physiological doses for adrenal or pituitary insufficiency) are not considered'
	b'ystemic treatment.'
	b'Systemic glucocorticoid therapy (excluding local glucocorticoids by nasal spray,'
	b'inhalation or other routes) or any other form of immunosuppressive therapy is in'
	b'progress within 7 days before the first dose.'
	b'Note: it is allowed to use physiological dose of glucocorticoid (Prednisone\\u226410 mg/d or'
	b'equivalent drug).'
	b'Received allogeneic organ transplantation (except corneal transplantation) or'
	b'allogeneic hematopoietic stem cell transplantation.'
	b'Allergic to study drug(sintilimab, pemetrexed, carboplatin, albumin-bound paclitaxel)'
	b'components excipients.'
	b'Not fully recovered from toxicity and/or complications caused by any intervention'
	b'before treatment (\\u2264level 1 or reach baseline, excluding fatigue or hair loss).'
	b'Has a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibody'
	b'positive).'
	b'Untreated active Hepatitis B (defined as HBsAg positive and HBV-DNA copies>ULN).'
	b'Active Hepatitis C (HCV antibody positive and HCV-RNA level higher than the detection'
	b'limit).'
	b'Inoculate the live vaccine within 30 days before the first dose (cycle 1 day 1).'
	b'Note: it is allowed to receive the injection inactivated virus vaccine for seasonal'
	b'influenza within 30 days before the first dose; however, it is not allowed to accept the'
	b'live attenuated influenza vaccine for intranasal medication.'
	b'Pregnant or lactating women.'
	b'There are any serious or uncontrollable systemic diseases, such as:'
	b'Resting ECG has significant abnormalities in rhythm, conduction or morphology,'
	b'and the symptoms are serious and difficult to control,such as complete left'
	b'bundle branch block, heart block above degree \\u2161, ventricular arrhythmia or atrial'
	b'fibrillation;'
	b'Unstable angina, congestive heart failure, chronic heart failure with NYHA grade'
	b'\\u2265 2;'
	b'Within 6 months before inclusion, there were any arterial thrombosis, embolism or'
	b'ischemia, such as myocardial infarction, unstable angina, cerebrovascular'
	b'accident, transient ischemic attack etc;'
	b'History of noninfectious pneumonia requiring glucocorticoid treatment within 1'
	b'year before the first dose,or having currently clinical active interstitial lung'
	b'diseases;'
	b'Active pulmonary tuberculosis;'
	b'Active or uncontrolled infections requiring systemic treatment;'
	b'Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic'
	b'active hepatitis;'
	b'poorly controlled diabetes (Fasting blood glucose (FBG)\\uff1e10mmol/L);'
	b'Urine routine test indicates that urine protein\\u2265++, and confirmed that 24 hours'
	b'proteinuria\\uff1e1.0 g;'
	b'Patients with mental disorders who are unable to cooperate with the treatment;'
	b'There are medical history, disease, treatment or laboratory abnormal results that may'
	b'interfere with the test results, prevent the subjects from participating in the whole'
	b'process of the study, or the researchers think that participating in the study is not'
	b'in the best interests of the subjects or there are other potential risks that the'
	b'ubjects are not suitable for the study.'

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

granulocyte colony stimulating factor

proteinuria

myocardial infarction

colony stimulating factor

liver disease

adjuvant therapy

blood test

transient ischemic attack

mental illness

sintilimab

interstitial lung disease

blood pregnancy test

non-small cell lung cancer

small cell lung cancer

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC neoSCORE